Hotline: 1800 102 2007
Hotline: 1800 102 2007
Search Business Opportunities
Merger 2015-03-26

Sun Pharma to delist Ranbaxy from BSE post completion of $4 billion merger

With the completion of $4 billion acquiring of Ranbaxy by Sun Pharma, shareholders of the former are expected to receive 0.8 share of Sun Pharma for each share of Ranbaxy.

Sun Pharma to delist Ranbaxy from BSE post completion of $4 billion merger

Sun Pharmaceutical announced that Ranbaxy will be delisted from the Indian Stock Exchange as their $4 billion merger is completing.

Reportedly, while filing to the BSE, Sun Pharma said, “Following the closure of this transaction, Ranbaxy will be delisted from the Indian Stock Exchanges. Ranbaxy shareholders will receive 0.8 share of Sun Pharma for each share of Ranbaxy.”

Worth mentioning here is the fact that the merger has fortified Sun Pharma’s position as the world’s fifth largest speciality generic pharmaceutical firm and the top ranking Indian Pharma Company with significant lead in market share, added the brand.

Commenting on the matter, Dilip Shanghvi, MD, Sun Pharma said, “We will continue to focus on gaining trust of the regulators globally while continuing to develop products based on patient needs and leverage them to become brand leaders globally.”

The combined entity’s manufacturing footprint covers five continents with products sold in over 150 nations with a stronger presence in the US, India, Asia, Europe, South Africa, CIS & Russia and Latin America.

Post-merger, Daiichi Sankyo becomes the second largest shareholder in Sun Pharma and both the companies will work together to leverage this relationship for global business growth, said Sun Pharma.

Meanwhile, Sun Pharma Chairman Israel Makov said, “The combined entity will capitalize on the expanded global footprint and enhance our dominance as a world leader in the speciality generics landscape.”

Ranbaxy has been facing issues raised by the FDA, US authorities and health regulators in the European markets.

In 2013, it had pleaded guilty to ‘felony charges’ relating to manufacture and distribution of certain adulterated drugs made at two India units, the US subsidiary of Ranbaxy had agreed to pay $500 million in settlement with the US authorities.

Significantly, Sun Pharma said three key priority levers to drive growth in the combined entity have been identified which includes achieving 100 per cent compliance in manufacturing in line with Regulator expectations, increase R&D productivity to introduce new innovative products and strong business growth across the US, India, and rest of the world markets.

Comment
image
image
image
Related opportunities
  • Others Food Service
    About Us: Wicked China is a place that serves up Chinese..
    Locations looking for expansion Maharashtra
    Establishment year 2000
    Franchising Launch Date 2018
    Investment size Rs. 2 Cr. - 5 Cr
    Space required 2500
    Franchise Outlets -NA-
    Franchise Type Unit
    Headquater Mumbai Maharashtra
  • Building decoration products
     About Us: We are one of the leading players in the..
    Locations looking for expansion Karnataka
    Establishment year 2004
    Franchising Launch Date 2018
    Investment size
    Space required 360
    Franchise Outlets -NA-
    Franchise Type -NA-
    Headquater Bangalore Karnataka
  • Gardening services
    About Us: Started in 2013, with a dream to convert concrete..
    Locations looking for expansion Rajasthan
    Establishment year 2013
    Franchising Launch Date 2018
    Investment size Rs. 10lac - 20lac
    Space required 200
    Franchise Outlets -NA-
    Franchise Type Unit
    Headquater Jaipur Rajasthan
  • “INVESTORS who are INDUSTRIOUS, with a budget of 30 LAKHS..
    Locations looking for expansion Andhra pradesh
    Establishment year 2017
    Franchising Launch Date 2017
    Investment size Rs. 20lac - 30lac
    Space required 1000
    Franchise Outlets -NA-
    Franchise Type Unit
    Headquater Hyderabad Andhra pradesh
Insta-Subscribe to
The Franchising World
Magazine
For hassle free instant subscription, just give your number and email id and our customer care agent will get in touch with you
OR Click here to Subscribe Online
Daily Updates
Submit your email address to receive the latest updates on news & host of opportunities
More Stories

Free Advice - Ask Our Experts